	US 12,337,023 B2
	Methods and compositions for the prevention and treatment of disease
D. Travis Wilson, Newton, MA (US)
Assigned to STEALTH BIOTHERAPEUTICS INC., Needham, MA (US)
Filed by Stealth BioTherapeutics Inc., Needham, MA (US)
Filed on Jun. 22, 2022, as Appl. No. 17/846,686.
Application 16/994,799 is a division of application No. 15/504,944, granted, now 10,744,178, issued on Aug. 18, 2020, previously published as PCT/US2015/046130, filed on Aug. 20, 2015.
Application 17/846,686 is a continuation of application No. 16/994,799, filed on Aug. 17, 2020, granted, now 11,376,304.
Claims priority of provisional application 62/040,236, filed on Aug. 21, 2014.
Prior Publication US 2023/0043587 A1, Feb. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/07 (2006.01); A61K 31/165 (2006.01); A61K 31/192 (2006.01); A61K 31/727 (2006.01); A61K 31/737 (2006.01); A61K 38/06 (2006.01); A61K 38/13 (2006.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61P 7/06 (2006.01); A61P 9/12 (2006.01); A61P 13/12 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01)

CPC A61K 38/07 (2013.01) [A61K 31/165 (2013.01); A61K 31/192 (2013.01); A61K 31/727 (2013.01); A61K 31/737 (2013.01); A61K 38/06 (2013.01); A61K 38/13 (2013.01); A61K 38/1875 (2013.01); A61K 45/06 (2013.01); A61P 7/06 (2018.01); A61P 9/12 (2018.01); A61P 13/12 (2018.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01)]

12 Claims

1. A method for reducing the risk of Alport Syndrome symptoms in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH₂or a pharmaceutically acceptable salt thereof.